Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.

BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX

Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.

Reasons to Retain BSX Stock in Your Portfolio for Now

BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.

Boston Scientific Stock Set to Gain From Completion of Axonics Deal

On Saturday, Boston Scientific Corporation BSX unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device.

Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO , Nov. 16, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.

Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial

Boston Scientific Corporation (NYSE:BSX ) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Nick Spadea-Anello - VP & GM of Interventional Cardiology Conference Call Participants Danielle Antalffy - UBS Danielle Antalffy So good morning, everyone. Thanks so much for joining us.

Boston Scientific Corporation (BSX) UBS Global Healthcare Conference (Transcript)

Axonics ModulationTechnologies Inc

MARLBOROUGH, Mass. , Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.

Boston Scientific Closes Acquisition of Axonics, Inc.

Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Kidney Stone Management Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global market size for kidney stone management reached a value of USD 1.80 billion in 2023. The market is expected to grow at a CAGR of 5.20% between 2024-2032 and attain a value of USD 2.84 billion by 2032.

Kidney Stone Management Market Forecast Report, 2024-2032 - Cook Group, Richard Wolf, Boston Scientific, and Dornier MedTech Actively Engaged in M&As to Increase Share

MARLBOROUGH, Mass. , Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024.

Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference

Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass. , Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company.

Boston Scientific Announces Agreement to Acquire Cortex, Inc.

Boston Scientific Corporation (NYSE:BSX ) Business Update Earnings Conference Call October 30, 2024 4:00 PM ET Company Participants Jonathan Monson - Senior Vice President of Investor Relations Joseph Fitzgerald - Executive Vice President and Group President, Cardiology Lance Bates - Senior Vice President and President Janar Sathananthan - Chief Medical Officer Kenneth Stein - Chief Medical Officer Conference Call Participants Operator Good day, and welcome to the Boston Scientific Cardiology Business Update. [Operator Instructions] Please note, this event is being recorded.

Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term

BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.

Boston Scientific Stock Gains From Market Expansion, Innovation

General Electric

Progressive

QUALCOMM

S&P Global

The Progressive, Qualcomm, GE Aerospace, S&P Global and Boston Scientific are included in this Analyst Blog.

The Zacks Analyst Blog The Progressive, Qualcomm, GE Aerospace, S&P Global and Boston Scientific

Medical devices maker Boston Scientific should continue to grow profitably through the next several years. Backing that bullishness is its history, good margins, pipeline, capital allocation, and more. While all other Seeking Alpha analysts have rated it a Hold this year, I have a Buy rating and expect the price to grow nearly 15% in the coming year.

Why The Fundamentals Make Me Bullish On Boston Scientific

Boston Scientific (BSX) possesses solid growth attributes, which could help it handily outperform the market.

Looking for a Growth Stock? 3 Reasons Why Boston Scientific (BSX) is a Solid Choice

These five stocks have provided double-digit returns year to date. Despite the rally, these stocks have double-digit upside potential for the short term.

Buy 5 S&P 500 Stocks to Tap Potential Short-Term Price Appreciation

On Wednesday, Boston Scientific Corporation BSX released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe, symptomatic aortic stenosis at risk of open-heart surgery.

Why is Boston Scientific Stock Trading Lower On Wednesday?

Haemonetics

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?

HAE vs. BSX: Which Stock Is the Better Value Option?

MARLBOROUGH, Mass. and WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery.

ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024

Here is how Boston Scientific (BSX) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

Boston Scientific (BSX) shares fell Wednesday when the medical equipment manufacturer's third-quarter profit fell and its GAAP earnings per share (EPS) came in short of its guidance.

Boston Scientific Profit Falls Even as Demand for Its Heart Products Surges

Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.

BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls

Boston Scientific Corporation (NYSE:BSX ) Q3 2024 Earnings Conference Call October 23, 2024 8:00 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Michael Mahoney - Chairman and Chief Executive Officer Daniel Brennan - Executive Vice President and Chief Financial Officer Kenneth Stein - Senior Vice President, Global Chief Medical Officer Conference Call Participants Robert Marcus - JPMorgan Joanne Wuensch - Citigroup Inc. Lawrence Biegelsen - Wells Fargo Securities Frederick Wise - Stifel, Nicolaus & Company David Roman - Goldman Sachs Patrick Wood - Morgan Stanley Travis Steed - Barclays Bank Danielle Antalffy - UBS Anthony Petrone - Mizuho Group Vijay Kumar - Evercore ISI Matt Miksic - Barclays Joshua Jennings - TD Cowen Matthew O'Brien - Piper Sandler Operator Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings Call. All participants will be in listen-only mode.

Boston Scientific Corporation (BSX) Q3 2024 Earnings Call Transcript

The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News for Boston Scientific Stock (BSX)